PG19 THE COST-EFFECTIVENESS OF HIGH-DOSE INTRAVENOUS ESOMEPRAZOLE IN PEPTIC ULCER BLEEDING: A DECISION-TREE MODEL WITH SPANISH COSTS AND NEW CLINICAL DATA  by Barkun, A et al.
Several UK primary care organizations consider alginates to be
interchangeable and differentiate products solely on costs; as
such many have implemented alginate substitution programs.
The aim of this study was to evaluate the validity of alginate
substitution programs by conducting an economic evaluation of
the costs and outcomes of the two leading prescribed alginates in
the UK. METHODS: A decision-analytic model was constructed
based on cohort of 3367 patients starting alginate monotherapy
in primary care. Transition probabilities were derived from
observed switching patterns during the observation period. The
model was populated with previously reported health state utili-
ties to derive quality-adjusted life years (QALYs). Costs were
derived from treatment pathways examining 1st line of therapy /
initial therapy, and subsequent therapies (eg, 2nd line, 3rd line,
etc). Costs were calculated by summing all lines of treatment
prescribed over one year including the costs of clinical con-
sultations. The model calculated incremental cost-effectiveness
between GA and Peptac after 2 lines and 5 lines of therapy.
RESULTS: The average annual incremental cost difference
between patients starting monotherapy GA and Peptac after
2-lines and 5-lines of therapy was £2.04 and £3.06, respectively.
Disaggregation of costs indicated there was an increased propor-
tion of a cost attributed to consultation visits for those starting
on Peptac attributed to higher switching rates requiring a GP
consultation. The incremental cost per quality adjusted life year
for 2nd line and 5th line was £2887 and £5305 per QALY. In the
sensitivity analysis the model was insensitive to changes in QoL
scores attributed to failing therapy. The cost per QALY ﬁgures
were moderately inﬂuenced by the duration of treatment failure
before commencing 2nd line therapy. CONCLUSIONS: Based on
aggregated costs of therapy and reduced switching rates Gavis-
con Advance was cost-effective compared to Peptac. We suggest
that all alginates are clinically not the same and that a broader
range of costs and impact on patients should be taken into
consideration when implementing therapeutic substitution
programs.
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OBJECTIVES: Recent clinical trials have conﬁrmed that hepa-
titis C patients who failed to attain a sustained virologic
response (SVR) on interferon-based therapy (pegylated or non-
pegylated) may still attain SVR if they are re-treated with pegy-
lated interferon alfa 2b therapy in combination with ribavirin.
On the basis of the international EPIC trial, a license has been
granted for pegylated interferon alfa 2b and ribavirin to be
used in this type of re-treatment. We developed a cost-
effectiveness for this retreatment paradigm in Scotland, as part
of our manufacturer submission to the Scottish Medicines Con-
sortium. METHODS: Local costs were sourced and outcomes
data from the EPIC trial were applied. Utilities and disease pro-
gression parameters were sourced from widely published and
well-established sources including the British HTA report on
hepatitis C. Our base case cost-effectiveness model compared
the retreatment with no retreatment—this comparison reﬂects
the current available treatment options in Scotland. RESULTS:
Our base case model found retreatment with pegylated inter-
feron alfa 2b plus ribavirin to be a cost-effective therapy com-
pared with no retreatment. The ICER was £11,389/QALY in
the base case, however this cost-effectiveness measure varied
strongly by the genotype of the virus patients are carrying as
well as by the patient’s prior experience on therapy (i.e. why
they originally failed to attain SVR). Patients with less virulent
strains of hepatitis C and whose prior treatment failed due to
relapse or non-compliance represent the most cost-effective
subgroup with ICERs below £9000/QALY. CONCLUSIONS:
Aside from the differences in ICERs associated with the differ-
ent sub-groups identiﬁed, ICERs remained below the cost-
effectiveness threshold in the most typical treatment scenarios
suggesting that the therapy will be a cost-effective addition to
the Scottish treatment system.
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OBJECTIVES: Peptic ulcer bleeding (PUB) is a serious and life-
threatening condition. Currently, no proton pump inhibitor has a
label for being used in this setting. A recent multinational clinical
trial (ClinicalTrials.gov identiﬁer: NCT00251979) showed that
high-dose intravenous esomeprazole (HIE), when administered
after endoscopic haemostasis to patients with bleeding ulcers, is
effective in preventing re-bleeding. METHODS: A decision-tree
model was built, including patients with PUB following success-
ful endoscopic haemostasis performed within 24 hours of initial
presentation, comparing HIE (80 mg infusion, then 8 mg/h for 3
days) versus placebo, with both groups receiving oral esomepra-
zole 40 mg daily from days 4 to 30. The model adopted a 30-day
time horizon, using a Spanish third-party payer perspective. The
outcome was the rate of averted re-bleeds. Probabilities and
lengths of hospital stay were provided from the recent trial.
Hospital costs, including physician fees, and data for other
model assumptions were retrieved from the literature. RESULTS:
Re-bleed rates were 7.7% (n = 375) for HIE, and 13.6%
(n = 389) for the placebo group (p < 0.01). The average costs per
patient for the HIE and placebo strategies were €4924 and
€4994, respectively. Thus, HIE was the dominant strategy (both
more effective and less costly than placebo). Sensitivity analysis
conﬁrmed the robustness of the results, with the placebo strategy
being less expensive only under speciﬁc circumstances (eg. when
signiﬁcantly varying re-bleed rates or dropping the hospitaliza-
tion costs for patients with a re-bleed). CONCLUSIONS: Based
on recent high-quality clinical trial data and modelling, the high-
dose intravenous esomeprazole strategy was more effective and
less costly than the placebo strategy.
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